
Sign up to save your podcasts
Or
Send us a text
We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.
Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.
Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.
Rob, Regina and Calum discuss:
This podcast was originally broadcast as a live webinar on 17th November 2021. To learn more and request a copy of the slides used please visit our website.
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence
3
22 ratings
Send us a text
We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.
Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.
Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.
Rob, Regina and Calum discuss:
This podcast was originally broadcast as a live webinar on 17th November 2021. To learn more and request a copy of the slides used please visit our website.
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence
40 Listeners
478 Listeners
122 Listeners
318 Listeners
84 Listeners
108 Listeners
29 Listeners
147 Listeners
41 Listeners
0 Listeners
0 Listeners
11 Listeners
11 Listeners